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Abstract
The matrix metalloproteinase matrilysin (MMP-7) has
been demonstrated to contribute to tumor development.
We have shown previously that members of the TNF
family of apoptosis- inducing proteins are substrates for
this enzyme, resulting in increased death pathway
signaling. The goal of the current study was to reconcile
the proapoptotic and tumor-promoting functions of
matrilysin. In the human HBL100 and murine NMuMG
cell lines that represent early stages of tumor progres-
sion and that express both Fas ligand and its receptor,
exposure to matrilysin results in cell death that can be
blocked by FasL neutralizing antibodies. Constitutive
expression of matrilysin in these cell lines selects for
cells with reduced sensitivity to Fas-mediated apopto-
sis as demonstrated both with a receptor-activating
antibody and with in vitro activated splenocytes.
Matrilysin-expressing cells are also significantly less
sensitive to chemical inducers of apoptosis. We pro-
pose that the expression of matrilysin that has been
reported at early stages in various tumor types can act
to select cells with a significantly decreased chance of
removal due to immune surveillance. As a result, these
cells are more likely to acquire additional genetic
modifications and develop further as tumors. Neoplasia
(2001) 3, 459–468.
Keywords:matrix metalloproteinase, Fas ligand, tumor progression, immune surveillance,
drug resistance.
Introduction
Malignant transformation occurs as a stepwise progression
from normal cells to a fully metastatic tumor. During this
progression, a set of traits must be acquired by cancer cells
to ensure their continued existence. The necessary capa-
bilities have been described as follows: autonomous growth
signaling, disregard for cell cycle checkpoints, resistance to
programmed cell death, immortalization, sustained angio-
genesis, and tissue invasion and metastasis [1]. The ability
to resist apoptotic signals is a trait strongly selected for in
tumor development as there are a number of points at which
an apoptotic signaling cascade can be initiated resulting in
the destruction of the tumor. These steps may include an
immune response, a hypoxic environment that can occur
before establishment of an adequate blood supply, and
anoikis, a form of cell death known to be induced through loss
of integrin-mediated matrix contacts [2 ]. In addition to
preventing removal of the tumor, resistance to apoptosis
also creates a permissive environment for genetic instability
allowing tumor cells to acquire additional genetic mutations
without triggering a suicide response. Thus, the multiple
stages at which death signals must be overcome and the
benefits likely to accrue to a resistant tumor cell suggest that
acquisition of resistance to apoptosis would be a strongly
selected trait.
Matrilysin (MMP-7, E.C. 3.4.24.23) is a member of a
multiple enzyme family, the matrix metalloproteinases
(MMPs), which have been principally associated with
degradation of extracellular matrix (ECM) components [3 ].
As ECM-degrading enzymes, the MMPs have been linked
with tumor invasion and metastasis, and this has led to the
development of synthetic MMP inhibitors as anti - invasive
and antimetastatic therapies [4]. Preliminary evidence from
phase III clinical trials of these agents have shown them to be
of little benefit to patients with advanced cancers although in
patients with earlier stage disease, survival benefits have
been observed [5]. This may be explained by recent
evidence, which implicates MMP activity in tumor growth
[6] and angiogenesis [7 ]. Unlike many other MMPs, which
are expressed as a host stromal response to a tumor,
matrilysin is produced by tumor cells themselves at an early
stage [8]. This has been observed in adenomas or
premalignant lesions of the intestine, stomach, prostate,
breast, and ovary [9–14]. Using genetically manipulated
animals, a definite role for matrilysin in early tumor develop-
ment has been established. Ablation of matrilysin significantly
reduced tumor formation by 67% in the multiple intestinal
neoplasia (Min) mouse model of intestinal cancer [15].
Conversely, overexpression of matrilysin in the mammary
glands of MMTV-neu mice, a mouse model of mammary
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carcinogenesis, significantly accelerated tumor development
[16]. In both of these models, an oncogenic switch (Apc
mutation in the Min mouse or neu expression in the MMTV-
neu mouse) was already present; however, matrilysin
expression considerably influenced the tumorigenic potential
of this mutation. The mechanism by which the MMP
matrilysin contributes to early tumor growth is unknown.
Previously, we have shown that two members of the TNF
family of proteins, TNF- and Fas ligand (FasL), are
substrates of matrilysin in specific circumstances [17,18].
FasL is a type II membrane protein expressed by activated T
cells, natural killer (NK) cells and in cells of immune-
privileged tissues such as eye and testis [19]. Expression of
FasL is frequently observed in a number of tumor types,
including melanoma, breast, and colon [20]. Binding of FasL
to the widely expressed Fas cell -surface receptor activates
an apoptotic signal cascade. Although coexpression of
ligand and receptor may suggest an apoptotic event, we
have previously shown that this does not necessarily occur
and speculate this is due to spatial constraints. Solubilization
of FasL by matrilysin results in an active death- inducing
protein free to interact with the receptor [18]. Here we show
that the enzyme matrilysin, acting on its substrate FasL,
promotes apoptosis in early tumor cells. Chronic exposure to
matrilysin, however, acted as a selective pressure for
apoptotic resistance. Cells selected in this manner were
significantly less sensitive to both Fas-mediated and chemi-
cally induced apoptosis. Thus, we propose a model whereby
matrilysin expression in precancerous cells confers a
survival advantage and promotes the development of a
tumor, explaining the apparent contradictory effects of
matrilysin on apoptosis and tumor progression.
Materials and Methods
Cell Lines and Expression Vectors
NMuMG (CRL 1636) and HBL100 (HTB 124) cell lines,
obtained from the ATCC, were maintained at 378C, 5% CO2
in DMEM (Gibco BRL, Long Island, NY) containing 10%
FCS (Atlanta Biologicals, Morcross, GA). The NMuMG line
also required 10 g/ml insulin (Sigma, St. Louis, MO). For
selection following transfection, G418 (Mediatech, Herndon,
VA) was added at 800 g/ml, which was decreased to 200
g/ml for maintenance. Human matrilysin cDNA [21] cut
with HindIII and XbaI was subcloned into the pRc/RSV
expression vector ( Invitrogen, Carlsbad, CA). HBL100 cells
were transfected with this expression plasmid or empty
vector using Superfect (Qiagen, Valencia, CA). NMuMG
cells were infected with a retrovirus constructed by inserting
the human matrilysin cDNA cut with EcoRI into the LXSN
vector [22]. Constructs were verified by DNA sequencing.
Antibodies and Other Reagents
Antibodies used were rat monoclonal anti -matrilysin [23],
rabbit anti -Fas (N-18, Santa Cruz Laboratories, Santa Cruz,
CA) and anti -FasL (C-178, Santa Cruz); monoclonal anti -
Fas (clone 13, Transduction laboratories, San Diego, CA);
monoclonal anti -human Fas clone CH11 (Upstate Bio-
logicals, Lake Placid, NY); monoclonals anti -mouse FasL
clone Kay-10, anti -human FasL clone NOK-2, anti -human
FasL clone G247-4, and monoclonal anti -mouse Fas clone
JO-2 (all from Pharmingen, San Diego, CA). Appropriate
isotype controls were obtained from Pharmingen. For
induction of apoptosis, the CH11 and JO-2 antibodies were
used at concentrations between 0.025 and 0.5 g/ml. For
neutralization studies, the NOK-2 antibody was used at
1 g/ml and was preincubated with conditioned media at
room temperature for 1 hour. Fas-Fc, the human Fas
receptor fused to an immunoglobulin Fc domain (Pharmin-
gen) was used at 3 g/ml for immunoprecipitation.
Recombinant active human matrilysin was from Calbio-
chem (La Jolla, CA). Cycloheximide and staurosporine were
obtained from Sigma. The cycloheximide was used at a
concentration of 1 g/ml. Staurosporine, solubilized in
dimethyl sulfoxide (DMSO, Sigma) was used at the
concentrations indicated for each experiment. Mitomycin C
was obtained from LKT laboratories, St. Paul, MN, and was
used in the concentration range of 2.5 to 50 g/ml.
Growth and Proliferation Assays
To determine the proliferation rate for each of the vector
control and matrilysin-expressing clones, thymidine incor-
poration was measured. Cells (3105) were plated on
35-mm dishes and left to adhere overnight. Methyl - 3H-
thymidine (NEN, Boston, MA; 1 Ci) was added to each
plate and the plates incubated for 24 hours. The cells were
washed, lysed in SLS buffer (1% sodium lauryl sulfate, 0.3 N
NaOH), and were harvested by scraping. Aliquots of the
lysate were analyzed for protein content using the BCA
assay (Pierce, Rockford, IL). Four hundred microliters of
lysate from each plate was placed in a scintillation vial with
10 ml of scintillation fluid (Eco-Lume, ICN, Costa Mesa, CA)
and the amount of isotope present measured using a
Beckman scintillation counter.
To measure clonal growth, 500 cells of each of the clones
were placed on 60 mm plates in complete growth medium
and incubated for 9 days with two changes of medium. At this
time the medium was aspirated and the cells were fixed with
cold acetic acid:methanol (1:3) for 5 minutes. The cells were
then rinsed and stained with crystal violet (Sigma). The
number of visible colonies on each plate was counted.
Apoptosis Assays
For flow cytometric analysis, cells were harvested and
washed in PBS with 5 mM EDTA. The cells were fixed with
70% ethanol, treated with RNase A (Sigma), and stained
with 50 g/ml propidium iodide (Sigma). The cells were
analyzed using a FACStar instrument (Becton Dickinson,
San Jose, CA) and data were processed with Flow-Jo
software (Treistar Enterprises, San Diego, CA).
For DNA laddering, cells were grown on 60 mm dishes,
treated as indicated for 22 hours, and then harvested by
scraping. They were washed in PBS and lysed in laddering
lysis buffer [1% NP-40; 20 mM EDTA; 50 mM Tris, pH 7.5].
Supernatants were RNase- treated at 378C for 2 hours and
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digested with proteinase K overnight at 558C. The DNA was
precipitated and resuspended in Tris–EDTA, pH 8.0.
Samples were normalized for DNA content, run on a 1.7%
agarose gel, and visualized with ethidium bromide staining.
For Hoechst staining, cells were grown on chamber slides
(Nunc). The cells were fixed in 25% (v/v) acetic acid /
methanol and incubated for 15 minutes with 0.1 g/ml
bisbenzimide (Hoechst 33258, Sigma). Cells were viewed
with a UV-equipped fluorescence microscope.
Protein Expression Analysis
Protein concentrations of samples were determined using
the BCA assay (Pierce) and equal quantities of protein were
used for Western blot analysis. Samples were electro-
phoresed through 12% SDS-PAGE gels and transferred to
nitrocellulose. The antibodies used were rat monoclonal
anti -matrilysin, mouse monoclonal anti -FasL (clone G247-
4), mouse anti -Fas (clone 13), and rabbit anti -FasL (N-18)
or anti -Fas (C-178). The blots were washed and incubated
with biotinylated anti -species secondary antibodies (Vector
Laboratories, Burlingame, CA). After washing, the blots were
incubated with streptavidin–HRP (Jackson Immuno-
Research, West Grove, PA). Signal was detected by
chemiluminesence (ECL, Amersham Pharmacia Biotech,
Piscataway, NJ).
To analyze cell -surface expression of FasL, cell -surface
proteins were labeled with biotin. The cells were washed in
cold PBS plus 0.1 mM CaCl and 1 mMMgCl2. The cells were
incubated on ice for 30 minutes with 1.5 mg/ml Sulfo-NHS-
LC-biotin (Pierce). Cells were washed with PBS plus
100 mM glycine and then with PBS containing 1% BSA.
The cells were lysed in lysis buffer (0.5% NP-40; 100 mM
NaCl; 50 mM Tris–HCl, pH 7.5). Equal quantities of lysates
were immunoprecipitated with recombinant Fas:Fc and
protein A-sepharose (Amersham Pharmacia Biotech). The
protein A-sepharose beads were washed five times with
lysis buffer, mixed with Laemmli sample buffer, boiled for
10 minutes, and loaded onto 12%SDS-PAGE gels. The gels
were blotted onto nitrocellulose and probed with streptavi-
din–HRP. Bands were visualized using chemiluminesence.
For flow cytometric analysis of cell -surface protein
expression, cells were harvested using 5% EDTA in PBS.
A total of 2105 cells per sample, suspended in 1% BSA in
PBS plus 0.1% sodium azide, were incubated with primary
antibody or a suitable isotype control for 1 hour on ice.
Antibodies used were rabbit anti -Fas (N-18) and mouse
anti -Fas (clone 13). After washing in BSA/PBS, cells were
incubated with FITC-conjugated secondary antibodies
(Gibco BRL) for 1 hour on ice. The cells were again washed
and analyzed using a FACStar instrument. Data were
processed using Flow-Jo.
T-cell– induced apoptosis spleen cell isolation was
performed as described [18]. Briefly, spleens from C57/Bl6
mice were macerated and splenocytes were isolated follow-
ing removal of red blood cells by hydrolysis. Activation was
achieved by incubation with 10 g/ml concanavalin A
(Sigma) and 5 ng/ml IL-2 (Gibco-BRL) at 378C for 8 hours.
The concanavalin A was removed by addition of 100 g/ml
 -methyl -mannoside (Sigma) for 20 minutes at 378C before
rinsing in RPMI medium. The cells were counted and
transferred to monolayers of NMuMG or HBL100 clones in
the presence of serum, cycloheximide, and insulin ( for
NMuMGs) such that the ratio of splenocytes to epithelial
cells was 5:1. After 6 hours, the monolayers were washed
with PBS until no splenocytes were visible on the plates. The
cells were then re- fed with DMEM containing serum,
cycloheximide, and insulin. After a further 16 hours, the cells
were harvested and stained with propidium iodide as above.
Results
Characterization of an In Vitro Model System
We hypothesized that the generation of sFasL by
matrilysin could promote tumor development by acting as a
selective pressure for apoptotic resistance. To test this, we
examined the effects of matrilysin on epithelial cells
representing early stages of tumor development that are
sensitive to Fas-mediated death. The NMuMG cell line was
established from normal murine mammary gland epithelium
[24] and has been reported to produce benign cystadeno-
mas [25] or to be nontumorigenic in mice [26]. HBL100 cells
were originally believed to represent normal human breast
epithelium [27] but, although ostensibly derived from breast
milk, a quality control analysis by the ATCC revealed the
presence of a Y chromosome.1 Importantly, they are
nontumorigenic when injected into nude mice and so are
considered a suitable model for our studies.
NMuMG and HBL100 cells were first characterized with
respect to matrilysin expression and the Fas pathway.
Neither cell line expressed matrilysin as determined by
western blotting of conditioned media (data not shown).
However, by Western blotting of total cell lysates, expression
of both the Fas receptor and its ligand FasL was observed
(Figure 1A ). To confirm that these proteins were localized to
the cell surface, flow cytometric analysis or cell -surface
biotinylation was performed. Cell -surface expression of
ligand and receptor was detected on both cell lines using
flow cytometry with two different antibodies for each antigen
(Figure 1B and data not shown). As there have been reports
that some of the antibodies to FasL may not detect this
antigen specifically, we also used a cell -surface biotinylation
procedure followed by immunoprecipitation with the Fas
receptor binding site linked to the immunoglobulin Fc domain
(Fas-Fc) to confirm cell -surface expression (Figure 1C ).
Thus, both NMuMG and HBL100 cells express Fas and FasL
on their cell surfaces.
To determine whether the Fas receptor was functional in
these cell lines, the cells were treated with a Fas receptor–
activating antibody for 22 hours. The cells were then
harvested for propidium iodide staining and flow cytometric
evaluation of DNA content or for DNA laddering experiments.
Apoptosis, as defined by either the presence of DNA ladders
following agarose gel electrophoresis (Figure 1D ) or a
1Information from ATCC: www.ATCC.org / phage / probline.html.
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subG1 peak in propidium iodide–stained cells analyzed by
flow cytometry occurred in Fas antibody–treated cells. The
NMuMG cell line required the presence of the protein
synthesis inhibitor cycloheximide to potentiate the antibody
response, a requirement reported previously for some cell
lines [28]. The HBL100 cells, however, underwent apoptosis
in response to antibody treatment alone. For the NMuMG
cells the percentage of population with a subG1 content of
DNA was 51.2±0.1 in the presence of the murine Fas-
activating antibody plus cycloheximide compared with
4.2±0.1 for a control IgG plus cycloheximide. In the case
of the HBL100 cells, the human Fas-activating antibody
resulted in a subG1 percentage of 21.4±2.9 compared with
6.1±1.1 for a control IgM.
Treatment with Matrilysin Induces Apoptosis in NMuMG and
HBL100 Cells
The characterization results showed that the NMuMG and
the HBL100 cell lines express both Fas and FasL and that
the Fas pathway is functional. To determine if matrilysin-
dependent solubilization of FasL could induce cell death in
the NMuMGs and HBL100s, the cells were treated with
increasing concentrations of recombinant active matrilysin
and the extent of apoptosis analyzed after 24 to 48 hours.
Apoptosis, as measured by the percentage of DNA with a
subG1 DNA content, was induced in these cell lines by
matrilysin in a dose-dependent manner (Figure 2A ). The
addition of 100 ng/ml of matrilysin resulted in a three- fold
increase in the apoptotic index in HBL100 cells and a two-
fold increase in NMuMG cells. To distinguish between an
effect on anoikis resulting from degradation of cell -produced
ECM and a Fas-mediated event, clarified conditioned media
from matrilysin- treated HBL100 cells was transferred to a
fresh monolayer of the same cells. This was performed in the
presence of serum, which contains the general proteinase
inhibitor,  -macroglobulin, to inhibit any residual matrilysin
activity in the transferred medium. As before, apoptosis was
induced in cells exposed to conditioned medium from
matrilysin- treated cells but not from untreated cells (Figure
2B ). The addition of a FasL-neutralizing antibody (NOK-2)
completely blocked the increase in apoptosis, indicating that
death was indeed mediated by sFasL (Figure 2B ). This
result is similar to a previously reported experiment in which
matrilysin-generated sFasL from murine splenocytes
induced apoptosis in the kidney cell line, 293, that could be
blocked by inclusion of a different FasL neutralizing antibody
(Kay-10) [18].
Establishment of HBL100 and NMuMG Lines Constitutively
Expressing Matrilysin
Previous work indicated that, following androgen with-
drawal, the normal epithelial cells of the prostate gland
express matrilysin and FasL and undergo apoptosis in a
Fas- and matrilysin-dependent manner [18]. In contrast,
studies with tumor cells indicate that early tumors (e.g.,
intestinal adenomas) express Fas [29], FasL [30], and
matrilysin [15], and yet consistently grow larger. To reconcile
this apparent discrepancy, we hypothesized that long- term
exposure to matrilysin-generated sFasL selected for cells
that have acquired resistance or lowered sensitivity to Fas-
mediated apoptosis. To test this, matrilysin was constitu-
tively expressed in the NMuMG and HBL100 cell lines.
Variant lines of both NMuMG and HBL100 were created by
stable expression of the human matrilysin gene under the
control of viral promoters. Control cells were infected or
transfected with the appropriate empty vector. After selection
in G418, viable colonies were formed in both matrilysin-
expressing as well as in vector control populations. Several
clones from the four populations were selected for expansion
and these clonal lines were used for further analysis.
Western blotting demonstrated the presence of matrilysin
in conditioned media from matrilysin- transfected clones
(Figure 3A ) whereas the vector -control clones remained
Figure 1. Fas and FasL are expressed and the Fas pathway is functional in
NMuMG and HBL00 cells. (A ) Western blotting of total cell lysates from
HBL100 and NMuMG cells for Fas and FasL, using the M20 anti - Fas and
C178 anti - FasL antibodies, respectively. (B ) Flow cytometric analysis of cell -
surface expression of Fas and FasL using the clone 13 anti - Fas and clone 33
anti - FasL antibodies. The solid black peak in each graph indicates the
background staining observed with a control IgG. Similar traces were obtained
when the M20 anti - Fas and C178 anti -FasL antibodies were used (not
shown ). (C ) Immunoprecipitation of biotinylated surface -associated FasL.
For each cell line, lysates from biotinylated cells were subjected to the
immunoprecipitation procedure in the absence (No I.P. ) or presence (Fas -Fc
I.P. ) of Fas -Fc protein. A band of approximately 40 kDa was specifically
detected in the I.P. lane for each cell line. (D ) Genomic DNA was isolated from
NMuMG or HBL100 cells that had been treated with the Fas -activating
antibodies Jo -2 and CH11, respectively ( + ) or isotype control (  ) and was
analyzed by agarose gel electrophoresis. Cycloheximide at a concentration of
1 g /ml was included with the NMuMG cells. The characteristic DNA
laddering pattern associated with apoptosis can be clearly seen in the Fas
antibody - treated lanes.
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negative. Analysis of conditioned media from these clones
indicated the presence of soluble FasL (sFasL) exclusively
in the matrilysin-expressing clones (Figure 3A ). Analysis of
proliferation by thymidine incorporation indicated that growth
rates were not significantly altered in the matrilysin-
expressing clones (Figure 3B ). Clonal growth ability did
not differ significantly from controls in three of the four
matrilysin-expressing clonal variants (Figure 3C ). One
HBL100 clone (Mat1) had reduced clonal growth, and
HBL100 clones were not used in subsequent experiments
where growth at low density was important. Fas receptor
levels were comparable in both matrilysin-expressing and
the vector control clones (3D), indicating that loss of
receptor was not a result of matrilysin expression.
Matrilysin-Expressing Clones Demonstrate Reduced
Sensitivity to Fas-Mediated Apoptosis
As the matrilysin-expressing clones appeared to be
viable despite their constant exposure to sFasL, we tested
their sensitivity to the Fas pathway. The cells were treated
with increasing concentrations of Fas-activating antibody in
the presence or absence of cycloheximide and the extent of
apoptosis 22 hours later analyzed by flow cytometric
evaluation of propidium iodide-stained cells. The amount
of apoptosis induced in antibody- treated matrilysin-
expressing cells was reduced by approximately 50%
compared to vector control cells in both the HBL100 and
NMuMG clones (Figure 4A C , F–H ). These results were
confirmed by Hoechst staining and counting of apoptotic
nuclei (Figure 4D ;E ; I and J ). The relative reduction in
sensitivity to the apoptosis- inducing effect was retained over
a concentration range of 0.025 to 0.5 g/ml of the Fas-
activating antibody (Figure 4B and G ).
Matrilysin-Expressing NMuMG Clones Demonstrate
Reduced Sensitivity to Drug- Induced Apoptosis
To test whether matrilysin-expressing clones were
resistant to other apoptotic stimuli, the NMuMG clones were
Figure 3. Matrilysin can be expressed in Fas -expressing cells. (A ). Western
blotting for matrilysin [ ‘‘MAT,’’ upper panels ] or sFasL [ lower panels ] from
48 -hour conditioned media from the indicated vector ( LXSN or RSV ) or
matrilysin - expressing (MAT ) clones. The antibodies used for detection of
sFasL were G-247 -4 anti - human FasL and Kay -10 anti -murine FasL. (B )
Measurement of tritiated thymidine incorporation in the various clones. (C )
Clonal growth analysis for each of the clones. Five hundred cells were plated
on plastic in growth medium and the number of visible colonies counted after
10 days. The asterisk indicates a result significantly lower than vector control
cells (P< .05 ). (D ) Cell - surface expression of the Fas receptor in each of the
clones. Antibodies used were the rabbit anti -Fas polyclonal antibody or a
rabbit IgG control followed by an FITC -conjugated anti - rabbit antibody. The
solid black peak represents the results obtained for the rabbit IgG and the clear
peak in each plot represents the result obtained for the anti -Fas antibody.
Results shown are representative of two separate analyses.
Figure 2. Short - term treatment with matrilysin induces cell death. (A )
NMuMG or HBL100 cells were treated with the indicated amounts of
recombinant activated matrilysin in the presence of 1 g /ml cycloheximide
( for NMuMGs ) in serum- free medium for 24 hours. The cells were harvested,
stained with propidium iodide, and analyzed by flow cytometry. The
percentage of cells with subG1 DNA (% apoptosis ) from three separate
experiments, performed in triplicate were used to calculate the mean± -
standard error (SEM). Asterisks indicate significant differences (P< .05 ) from
the untreated (0 ng /ml matrilysin ) samples, calculated using Student’s t test.
(B ) Serum- free conditioned medium was obtained from HBL100 cells treated
with 0 (CTL ) or 100 ng /ml matrilysin (MAT CM) for 48 hours. This CM was
filtered and incubated for 1 hour at room temperature with the NOK-2 anti -
FasL (FasL ) antibody or an IgG control ( IgG ). The medium was then
transferred to fresh monolayers of HBL100 cells in the presence of an equal
volume of serum-containing DMEM and incubated for 22 hours. The cells
were harvested, stained with propidium iodide and analyzed by flow
cytometry. The subG1 population from two separate experiments performed
in triplicate was used to calculate the mean±SEM for each condition.
*Indicates a significant difference from control, P= .0035. **Indicates a
significant difference from MAT CM+ IgG, P= .018.
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treated with staurosporine, an inhibitor of protein kinase C,
and mitomycin C, a DNA cross- linker. As described
previously, flow cytometry was used to assess the extent
of apoptosis as a result of drug treatment. When the NMuMG
cells were treated with increasing concentrations of staur-
osporine (0.1 to 1.0 M) for 20 or 40 hours, significant
resistance to cell death was observed in the matrilysin-
expressing clones compared to vector clones (Figure
5A and B, and data not shown). Mitomycin C induced low
levels of apoptosis in NMuMG cells after 20 hours of
treatment; however, a significant difference in response
was evident between the vector control and matrilysin-
expressing clones, with the matrilysin-expressing clones
demonstrating an approximately 80% reduction in apoptosis
(Figure 5C and D ). The effect of these drugs on apoptosis
was confirmed by Hoechst staining and identification of
apoptotic nuclei (data not shown). These data indicate that
matrilysin expression can select for cells with significantly
reduced sensitivity to a variety of apoptotic signals.
To investigate whether Fas stimulation alone could select
for the resistant phenotype, vector control and matrilysin-
expressing NMuMG clones were treated with Fas-activating
antibody (Jo-2) or IgG at 0.25 g/ml in the presence of
cycloheximide for 22 hours. The medium was then changed
Figure 5. Matrilysin - expressing NMuMG clones are significantly less sensitive to drug - induced apoptosis. (A ) Vector control ( LXSN: solid black line, squares ) or
matrilysin - expressing (MAT: dashed line, circles ) clones were treated with a range of concentrations of staurosporine (0.1 to 1.0 M) or an equivalent amount of
vehicle (DMSO) for 40 hours. The cells were then harvested, stained, and analyzed as before. The results for the two vector clones as well as for the two matrilysin -
expressing clones have been combined. (B ) The bar graph indicates the mean and SEM obtained for each independent clone at a staurosporine concentration of 1
M from three experiments. Results shown are fold over control where the control was treatment with an equivalent amount of vehicle (DMSO). (C ) Vector (LXSN)
and matrilysin (MAT ) clones were treated for 20 hours with mitomycin C over a concentration range of 2.5 to 40 g /ml. Following treatment the cells were harvested,
stained with propidium iodide, and analyzed by flow cytometry. The results obtained for two different vector and matrilysin -expressing clones were combined. The
results shown are fold over control where the control was treatment with an equivalent amount of vehicle ( sterile water ). (D ) The bar graph shows the results
obtained for one concentration of mitomycin C (50 g /ml ) after 22 hours of treatment. *Statistical significance was determined using Student’s t test (P .002 ).
Figure 4. Matrilysin -expressing clones demonstrate reduced sensitivity to Fas -mediated apoptosis. HBL100 (panels A–E ) and NMuMG (panels F–J ) cells were
treated with Fas - activating antibodies for 22 hours in the absence (HBL100 ) or presence (NMuMG) of cycloheximide. The cells were harvested and stained with
propidium iodide before analysis by flow cytometry. (A, F ) Representative samples of the tracings obtained for a vector - control (HBL100, RSV; NMuMG, LXSN )
and matrilysin - expressing (MAT ) clone from each cell line following exposure to isotype control or Fas -activating antibodies are shown. (B, G ) The vector - control
and matrilysin - expressing clones from each cell line were exposed to a range of concentrations of Fas - activating antibody. The results for both vector clones (RSV
or LXSN: solid line, squares ) or both matrilysin - expressing clones (MAT: dashed line, circles ) have been combined. (C, H ) Bar graphs showing the mean and SEM
obtained for the independent clones when an antibody concentration of 0.5 g /ml was used in three independent experiments. (D, I ) Sample photomicrographs
showing bisbenzimide -stained cells following exposure of the various clones to 0.5 g /ml antibody. The characteristic nuclear morphology associated with
apoptosis is clearly visible ( arrows ). (E, J ) Bar graphs represent the mean and SEM obtained for each clone following four separate experiments.
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and the cells maintained in low levels of the activating
antibody or IgG (0.025 g/ml) without cycloheximide for
9 days to allow outgrowth of surviving cells. The cells were
then exposed either to a second high dose of antibody in the
presence of cycloheximide or to mitomycin C. Vector control
cells that had been exposed only to IgG died as expected in
response to either anti -Fas (Figure 6A ) or mitomycin C
(Figure 6B ). In contrast, vector control cells that had been
selected in Fas-activating antibody demonstrated a resist-
ance phenotype to both stimuli similar to that seen with
matrilysin-expressing clones. The matrilysin-expressing
clones behaved similarly, irrespective of whether they had
been selected with IgG or anti -Fas. These results reinforce
our overall hypothesis that exposure to a Fas-activating
signal, such as matrilysin-generated sFasL or the agonistic
antibody, selects for cells with reduced sensitivity to
apoptosis.
Matrilysin-Expressing Cells Are Less Sensitive to
Immune-Mediated Killing
One of the earliest challenges to tumor establishment in
vivo is the host immune response. This is dependent on a
number of immune mechanisms, both innate and acquired
[31]. Among the best studied responses is the generation of
NK and cytotoxic T lymphocytes (CTLs) that can kill tumor
cells through two pathways, a perforin /granzyme pathway or
a FasL-dependent mechanism [30]. We therefore tested if
the observed decrease in sensitivity to apoptosis could
translate to a possible immune evasion mechanism. Murine
spleen cells were isolated and activated with concanavalin A
and interleukin-2 to upregulate FasL. The murine spleno-
cytes were incubated with monolayers of the allogeneic
NMuMG clones at a ratio of 5:1 for 6 hours. After this time,
the splenic lymphocytes were removed and the monolayers
rinsed five times before incubating overnight. The following
day, the cells were harvested, stained with propidium iodide,
and analyzed by flow cytometry for extent of apoptosis. The
vector control clones showed an apoptotic rate of approx-
imately 45% whereas the apoptotic rate of the matrilysin-
expressing clones was 20%, a greater than 50% reduction in
sensitivity (Figure 7 ). When murine splenocytes were
incubated with the xenogeneic HBL100 clones, a similar
trend was observed in that the percentage of apoptotic
matrilysin-expressing cells was only 27% compared to 43%
for the vector control clones (Figure 7 ). Thus, cells chroni-
cally exposed to matrilysin demonstrated reduced sensitivity
to challenge by activated lymphocytes.
Discussion
The MMP matrilysin has been demonstrated to contribute to
early stages of mammary and intestinal tumor progression
[15,16]. The substrates responsible for the tumor-promoting
activity of matrilysin have not been identified. Reported
substrates that could conceivably influence tumor progres-
sion include 4- integrin [32], E-cadherin [33], or the
Figure 7. Matrilysin - expressing clones demonstrate reduced sensitivity to
immune cells. Monolayers of each of the vector control (Vector ) or matrilysin -
expressing (MAT ) clones were incubated for 6 hours with freshly isolated, in
vitro activated splenocytes in the presence of 1 g /ml cycloheximide. The
monolayers were then washed extensively to remove the spleen cells and the
clones were further incubated for 16 hours, again in the presence of
cycloheximide. The cells were harvested, stained with propidium iodide and
the extent of apoptosis ( subG1 DNA) determined by flow cytometry. Results
shown are mean and SEM from three separate experiments. For each cell
line, the results obtained for two different vector and two matrilysin -
expressing clones were combined. Statistical significance was determined
using Student’s t test and the results are indicated with asterisks where **
represents P= .0014 and * represents P .03.
Figure 6. Exposure to the Fas -activating antibody selects for cells with
reduced apoptotic sensitivity. Vector control ( LXSN) and matrilysin - express-
ing (MAT ) NMuMG clones were treated for 22 hours with 0.125 g /ml anti -
Fas antibody ( Jo -2 ) or isotype control ( IgG ) in the presence of 1 g /ml
cycloheximide. The medium was then aspirated from the remaining plates and
the cells re - fed with growth medium containing 0.025 mg /ml Jo - 2 or IgG.
After 9 days, the cells were again treated for 22 hours with 0.125 g /ml anti -
Fas antibody in the presence of 1 g /ml cycloheximide (A ) or with 50 g /ml
mitomycin C (B ). At this point, the cells were harvested, stained with
propidium iodide and analyzed by flow. Results are mean and SEM from two
separate experiments.
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apoptosis- related proteins TNF- [17] and FasL [18]. In
previous work, we have shown that involution of a normal
prostate gland following androgen withdrawal is greatly
influenced by matrilysin and associated with induction of
prostatic epithelial cell apoptosis by matrilysin-generated
sFasL [18]. Many tumors are known to upregulate FasL
expression. Interestingly, in breast cancer specimens,
matrilysin and FasL may colocalize, as both have been
described as being expressed in normal-appearing epithe-
lium adjacent to tumor areas [13,34]. However, the
possibility that FasL was a relevant substrate for matrilysin
in early-stage mammary or intestinal tumorigenesis pre-
sented a conundrum, as increased apoptosis should result in
suppression rather than enhancement of tumorigenicity. It
has become increasingly clear that tumor cells develop
mechanisms to escape from the protective effects of
programmed cell death. Thus, we hypothesized that chronic
expression of matrilysin in the cellular precursors to breast or
colon cancer could result in the selection of a population of
cells with reduced sensitivity to apoptotic death. The results
presented in this work support this hypothesis. Constitutive
expression of matrilysin in epithelial cells that are sensitive to
apoptosis induced by matrilysin cleavage of FasL resulted in
at least a 50% reduction in the response of these cells to both
Fas-mediated and drug- induced cell death. Thus, we
speculate that these cells are more likely to survive additional
insults, accumulate genetic mutations, and convert to
malignancy. In particular, we report that these cells are
more likely to survive lymphocyte-mediated immune sur-
veillance mechanisms.
The activity of sFasL is a controversial topic. A number of
studies have shown that overexpression of a human sFasL
species equivalent to a naturally occurring form resulted in
limited cytotoxic activity, whereas a murine sFasL had no
cytotoxic activity [35,36]. The majority of these studies have
used Jurkat T cells or other cells of lymphoid origin as
targets. We have previously shown, using an epithelial target
cell line, that matrilysin-generated murine sFasL does have
cytotoxic activity [18]. Thus, we have proposed that the
nature of the target may affect its ability to be killed by sFasL.
A recent report shows that the presence of an accessory
molecule such as ICAM-1 on the target cell can influence the
cytotoxicity of FasL [37]. It is possible that other accessory
molecules on epithelial cells may potentiate the cytotoxic
activity of sFasL. Data presented in this paper illustrate that
acute exposure of FasL-expressing cells to matrilysin results
in the generation of a soluble factor whose activity can be
abrogated by incubation with a FasL neutralizing antibody,
thus suggesting that the factor is sFasL. However, we cannot
completely rule out the possibility that other TNF-related
molecules could be processed to a soluble form by matrilysin
and that anti -FasL antibodies may cross-react with these
molecules.
In addition to reports of sFasL being noncytotoxic, sFasL
has also been suggested to act antagonistically to the
membrane form of FasL [35]. That is, the soluble form
occupies receptors without inducing a cell -death cascade
while simultaneously blocking those receptors from access
by cytotoxic FasL. This is however, contrary to our
observation that parental cells expressing Fas and FasL do
not undergo apoptosis constitutively, whereas short - term
treatment with matrilysin resulting in the generation of a
soluble factor does initiate FasL-dependent cell death. The
generation of resistance in vector control cells following
repeated exposure to the Fas-activating antibody also
suggests that the mechanism of resistance is not through
blockade of the receptor by a nonsignaling soluble form of
the ligand. Finally, the cross- resistance to nonreceptor
stimuli such as staurosporine lends further support to loss
of sensitivity being due to something other than an
antagonistic form of FasL. We therefore, conclude that
matrilysin releases a proapoptotic form of sFasL, an
observation that does not rule out the possibility of inhibitory
forms of sFasL being generated by other enzymes.
Desensitization to Fas ligation following selection of
apoptosis- resistant cells through exposure to chemother-
apeutic agents has been described by a number of
investigators. This was initially thought to be a result of
these chemotherapeutic agents acting through the Fas/
FasL pathway. Recent evidence, however, indicates that the
majority of these agents do not in fact depend on the Fas/
FasL interaction for efficacy [38,39] and the consensus now
appears to be that only 5- fluorouracil has the potential to
involve Fas/FasL [40,41]. A recent paper describes how
matrilysin expression in tumor lines results in loss of
responsiveness to chemotherapeutic agents [42]. The
results are consistent with our findings with respect to
drug- induced apoptosis. However, the authors suggest that
the agents used exert their effects through FasL/Fas
interactions and that matrilysin activity removes FasL from
the cell surface, thus preventing it from participating in the
death signaling pathway. Our data indicating that matrilysin-
generated sFasL can initiate apoptosis contradicts the
conclusions reached by these authors. We have deliberately
chosen chemical agents that are not known to act through
the Fas pathway and have still demonstrated that matrilysin
expression leads to a loss of sensitivity. Our conclusion,
therefore, is that matrilysin expression, through generation of
a chronic Fas-activating signal, results in an alteration of the
apoptosis signaling pathway leading to a loss of sensitivity to
various death stimuli. The demonstration that cells can be
selected for resistance to drug- induced cell death following
incubation with the Fas-activating antibody supports this
theory.
The theory of immune surveillance contributing to the
eradication of tumor cells has been developed over many
years [43]. Much work has gone into identifying the cell types
responsible for this function of the immune system. A
competent immune system, principally CD8+ CTLs, has
been shown to act as a tumor suppressor in a study of
chemically induced tumors [44]. The Fas/FasL system has
been shown to play a role in immune surveillance and
deletion of tumor cells. Both NKs and CTLs can act to lyse
target cells through perforin /granzyme and Fas-mediated
pathways [45]. Evidence for the importance of the Fas
pathway has come from a number of different studies
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[46,47]. In vivo dependence of CTLs on the FasL pathway
has been shown using tumor cells overexpressing the Fas
pathway inhibitory protein, cFLIP [48]. Multiple reports have
shown that downregulation or mutation of the Fas receptor
occurs in a number of tumor types [49–52], and this is
thought to contribute to their ability to evade immune-
mediated deletion. Testing of the ability of tumor cells
expressing membrane-associated FasL to escape immune
surveillance has been hampered by the proinflammatory
response such tumor cells invoke. However, sFasL has also
been proposed as a mediator of the inflammatory response.
Although there have been suggestions that sFasL is
chemotactic for neutrophils [53], Hohlbaum et al. [54] have
shown that, in vivo, it is the membrane form of FasL that
results in neutrophil infiltration, whereas cells making a
soluble form do not generate this inflammatory response. In
fact, the soluble form can exert a protective anti - inflamma-
tory effect. Cells expressing a noncleavable membrane form
of FasL failed to form tumors, whereas cells expressing
sFasL efficiently formed tumors when injected subcutane-
ously into nude mice [54]. Tumor cells able to generate
sFasL therefore have an additional advantage in that they do
not promote a strong immune infiltration. This suggests a
model whereby matrilysin-expressing tumor cells generate
sFasL, thus downregulating a potential inflammatory
response and neutrophil infiltration while simultaneously
selecting for a FasL- resistant population of tumor cells.
Thus, any immune infiltration of the tumor that does occur is
ineffective so allowing the tumor to continue developing, an
observation supported in vitro by the matrilysin-expressing
clones being resistant to activated splenocytes.
Another way in which the Fas/FasL system can play a
role in tumor development is through the ‘‘Fas counter-
attack.’’ The expression of FasL by tumor cells can result in
the killing of Fas-expressing immune cells produced as a
host response to the tumor [55]. Although sometimes
disputed [56], this has been reported to occur in tumors of
the skin, intestine, liver, esophagus, and breast [34,57–60].
It is possible that a cleavage product of FasL released from a
matrilysin-expressing tumor could diffuse from the tumor
and result in the destruction of immune cells around it.
We have demonstrated that chronic exposure to matrily-
sin in premalignant epithelial cells that express Fas and FasL
can result in the selection of a subpopulation of cells that
display a decreased sensitivity to the death- inducing effects
of sFasL. The Fas/FasL system is one of the mechanisms
used by the immune surveillance system to eliminate
aberrant cells with the potential to become cancerous.
Because clonal selection of cells with robust proliferative
and survival properties is necessary for the progression and
continued development of a tumor, we propose that the
cleavage of FasL and development of resistant subpopula-
tions is a mechanism by which matrilysin contributes to early
stages of tumor progression. Additionally, such cells also
demonstrate a significantly reduced sensitivity to drugs that
stimulate apoptosis, suggesting a further benefit to a
developing tumor that allows it to escape the effects of toxic
therapies.
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